10-Q Filing

MERCK & CO., INC. CIK: 310158 Q3 2019

Filing Information

Form Type	10-Q
Accession Number	`0000310158-19-000042`
Period End Date	20190930
Filing Date	20191105
Fiscal Year	2019
Fiscal Period	Q3
XBRL Instance	mrk0930201910q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 56 Cash Flow Statement 72 Comprehensive Income 28

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$116.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$119.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$1.42B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$1.51B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$16.32B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.28B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.96B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.87B	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$149.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$899.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $116 in 2019 and $119 in 2018)	`AccountsReceivableNetCurrent`	$8.44B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $116 in 2019 and $119 in 2018)	`AccountsReceivableNetCurrent`	$7.07B	USD	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $1,515 in 2019 and $1,417 in 2018 classified in Other assets - see Note 6)	`InventoryNet`	$5.44B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $1,515 in 2019 and $1,417 in 2018 classified in Other assets - see Note 6)	`InventoryNet`	$5.86B	USD	Point-in-time
Treasury stock, shares (shares)	`TreasuryStockShares`	984.54M	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$3.83B	USD	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$4.50B	USD	Point-in-time
Treasury stock, shares (shares)	`TreasuryStockShares`	1.03B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$25.88B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$26.14B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$2.11B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$6.23B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,281 in 2019 and $16,324 in 2018	`PropertyPlantAndEquipmentNet`	$14.29B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,281 in 2019 and $16,324 in 2018	`PropertyPlantAndEquipmentNet`	$13.29B	USD	Point-in-time
Goodwill	`Goodwill`	$19.48B	USD	Point-in-time
Goodwill	`Goodwill`	$18.25B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$12.31B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$11.43B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$9.00B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$7.55B	USD	Point-in-time
Total Assets	`Assets`	$83.33B	USD	Point-in-time
Total Assets	`Assets`	$82.64B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$5.31B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.41B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.20B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.32B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$11.77B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$10.15B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$873.00M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.97B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.43B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.46B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$20.68B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$22.21B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$22.68B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$19.81B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.96B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.70B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$12.04B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$11.09B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2019 and 2018	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2019 and 2018	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.56B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$38.81B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$45.80B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$42.58B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.39B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.54B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$81.76B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$77.63B	USD	Point-in-time
Less treasury stock, at cost: 1,026,214,892 shares in 2019 and 984,543,979 shares in 2018	`TreasuryStockValue`	$50.93B	USD	Point-in-time
Less treasury stock, at cost: 1,026,214,892 shares in 2019 and 984,543,979 shares in 2018	`TreasuryStockValue`	$54.92B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$26.84B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$26.70B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$87.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$181.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.88B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$32.66B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.93B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.57B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$27.74B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$32.77B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$82.64B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$83.33B	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$12.40B	USD	1 Quarter
Sales	`Revenues`	$34.97B	USD	3 Qtrs
Sales	`Revenues`	$31.30B	USD	3 Qtrs
Sales	`Revenues`	$10.79B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.62B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.99B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$10.44B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$10.22B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.73B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.59B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.46B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.44B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$7.32B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.07B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.20B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$7.54B	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$171.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$494.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$232.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$444.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-362.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-35.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$172.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$512.00M	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.05B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$26.30B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$8.13B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$25.20B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$2.67B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$6.10B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$2.35B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$8.67B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$707.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.68B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$440.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.26B	USD	3 Qtrs
Net Income	`ProfitLoss`	$4.42B	USD	3 Qtrs
Net Income	`ProfitLoss`	$1.96B	USD	1 Quarter
Net Income	`ProfitLoss`	$1.91B	USD	1 Quarter
Net Income	`ProfitLoss`	$7.41B	USD	3 Qtrs
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$8.00M	USD	1 Quarter
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-73.00M	USD	3 Qtrs
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$6.00M	USD	1 Quarter
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$22.00M	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.39B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$7.49B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.95B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.90B	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.74	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.73	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$2.91	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.64	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$2.89	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.63	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.74	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.73	USD	1 Quarter

Cash Flow Statement 72 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$2.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$2.00M	USD	Point-in-time
Net income	`ProfitLoss`	$4.42B	USD	3 Qtrs
Net income	`ProfitLoss`	$1.96B	USD	1 Quarter
Net income	`ProfitLoss`	$1.91B	USD	1 Quarter
Net income	`ProfitLoss`	$7.41B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$2.72B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$3.52B	USD	3 Qtrs
Intangible asset impairment charges	`GoodwillAndIntangibleAssetImpairment`	-	USD	3 Qtrs
Intangible asset impairment charges	`GoodwillAndIntangibleAssetImpairment`	$864.00M	USD	3 Qtrs
Charge for acquisition of Peloton Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	-	USD	3 Qtrs
Charge for acquisition of Peloton Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	$982.00M	USD	3 Qtrs
Charge for future payments related to collaboration license options	`ChargeForLicenseOptionsRelatedToCollaboration`	$650.00M	USD	3 Qtrs
Charge for future payments related to collaboration license options	`ChargeForLicenseOptionsRelatedToCollaboration`	-	USD	3 Qtrs
Charge for collaboration termination	`GainLossOnContractTermination`	$-420.00M	USD	3 Qtrs
Charge for collaboration termination	`GainLossOnContractTermination`	-	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-391.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-386.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$261.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$306.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$101.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$91.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$-488.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$-219.00M	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.03B	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$3.47B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$8.65B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$7.33B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.69B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$2.34B	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$2.38B	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$6.90B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$11.24B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$7.46B	USD	3 Qtrs
Acquisition of Antelliq Corporation, net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Antelliq Corporation, net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$3.62B	USD	3 Qtrs
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$1.04B	USD	3 Qtrs
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	3 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$372.00M	USD	3 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$269.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$150.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-320.00M	USD	3 Qtrs
Net Cash (Used in) Provided by Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.87B	USD	3 Qtrs
Net Cash (Used in) Provided by Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$2.14B	USD	3 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$2.29B	USD	3 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-3.89B	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$3.01B	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	-	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$4.96B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$3.73B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$3.16B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.90B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$4.29B	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$461.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$344.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-289.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-240.00M	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-6.85B	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-7.59B	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-26.00M	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-140.00M	USD	3 Qtrs
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-96.00M	USD	3 Qtrs
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.73B	USD	3 Qtrs
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $2 million at January 1, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.87B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $2 million at January 1, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.10B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $2 million at January 1, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.97B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $2 million at January 1, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.83B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $2 million at September 30, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.87B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $2 million at September 30, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.10B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $2 million at September 30, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.97B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $2 million at September 30, 2019 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.83B	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.39B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$7.49B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.95B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.90B	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$27.00M	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$223.00M	USD	3 Qtrs
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-9.00M	USD	3 Qtrs
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$91.00M	USD	1 Quarter
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-56.00M	USD	3 Qtrs
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$109.00M	USD	3 Qtrs
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-17.00M	USD	1 Quarter
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$40.00M	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-106.00M	USD	3 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-41.00M	USD	3 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-15.00M	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-40.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-136.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$14.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-117.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-240.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-29.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$33.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$155.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-28.00M	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.43B	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$1.87B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$1.92B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$7.64B	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.